These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27190088)

  • 1. Copeptin, insulin-like growth factor binding protein-1 and sitagliptin: A report from the BEta-cell function in Glucose abnormalities and Acute Myocardial Infarction study.
    Arnetz L; Hage C; Brismar K; Catrina SB; Norhammar A; Lundman P; Wallander M; Ryden L; Mellbin L
    Diab Vasc Dis Res; 2016 Jul; 13(4):307-11. PubMed ID: 27190088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved glycemic control due to sitagliptin is not related to cortisol or the surrogate marker IGFBP-1 for hepatic insulin sensitivity.
    Arnetz L; Hage C; Ekberg NR; Alvarsson M; Brismar K; Norhammar A; Mellbin L
    Growth Horm IGF Res; 2015 Dec; 25(6):298-303. PubMed ID: 26283275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Copeptin and insulin-like growth factor binding protein-1 during follow-up after an acute myocardial infarction in patients with type 2 diabetes: A report from the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction 2 cohort.
    Smáradóttir MI; Catrina SB; Brismar K; Norhammar A; Gyberg V; Mellbin LG
    Diab Vasc Dis Res; 2019 Jan; 16(1):22-27. PubMed ID: 30309264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities--the BEGAMI study.
    Hage C; Brismar K; Efendic S; Lundman P; Rydén L; Mellbin L
    J Intern Med; 2013 Apr; 273(4):410-21. PubMed ID: 23331339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Copeptin in patients with acute myocardial infarction and newly detected glucose abnormalities - A marker of increased stress susceptibility? A report from the Glucose in Acute Myocardial Infarction cohort.
    Smaradottir MI; Ritsinger V; Gyberg V; Norhammar A; Näsman P; Mellbin LG
    Diab Vasc Dis Res; 2017 Mar; 14(2):69-76. PubMed ID: 28118730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of dextromethorphan as add-on to sitagliptin on blood glucose and serum insulin concentrations in individuals with type 2 diabetes mellitus: a randomized, placebo-controlled, double-blinded, multiple crossover, single-dose clinical trial.
    Marquard J; Stirban A; Schliess F; Sievers F; Welters A; Otter S; Fischer A; Wnendt S; Meissner T; Heise T; Lammert E
    Diabetes Obes Metab; 2016 Jan; 18(1):100-3. PubMed ID: 26362564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of sitagliptin on circulating zinc-α2-glycoprotein levels in newly diagnosed type 2 diabetes patients: a randomized trial.
    Tian M; Liang Z; Liu R; Li K; Tan X; Luo Y; Yang M; Gu HF; Liu H; Li L; Yang G
    Eur J Endocrinol; 2016 Feb; 174(2):147-55. PubMed ID: 26546612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS.
    Nauck MA; McGuire DK; Pieper KS; Lokhnygina Y; Strandberg TE; Riefflin A; Delibasi T; Peterson ED; White HD; Scott R; Holman RR
    Cardiovasc Diabetol; 2019 Sep; 18(1):116. PubMed ID: 31481069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
    Xu L; Man CD; Charbonnel B; Meninger G; Davies MJ; Williams-Herman D; Cobelli C; Stein PP
    Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial.
    van Genugten RE; van Raalte DH; Muskiet MH; Heymans MW; Pouwels PJ; Ouwens DM; Mari A; Diamant M
    Eur J Endocrinol; 2014 Mar; 170(3):429-39. PubMed ID: 24297090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of new-onset heart failure in patients using sitagliptin: a population-based cohort study.
    Eurich DT; Weir DL; Simpson SH; Senthilselvan A; McAlister FA
    Diabet Med; 2016 May; 33(5):621-30. PubMed ID: 26206341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD.
    Muanda FT; Weir MA; Bathini L; Clemens KK; Perkovic V; Sood MM; McArthur E; Sontrop JM; Kim RB; Garg AX
    Clin J Am Soc Nephrol; 2020 Dec; 15(12):1728-1739. PubMed ID: 33239410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl Peptidase-4 Inhibition Potentiates Stimulated Growth Hormone Secretion and Vasodilation in Women.
    Wilson JR; Brown NJ; Nian H; Yu C; Bidlingmaier M; Devin JK
    J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29478970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of vildagliptin and sitagliptin in lowering fasting plasma glucose: Results of a randomized controlled trial.
    Göke R; Eschenbach P; Dütting ED
    Diabetes Metab; 2015 Jun; 41(3):244-7. PubMed ID: 25457473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of sitagliptin on plaque changes in coronary artery following acute coronary syndrome in diabetic patients: The ESPECIAL-ACS study.
    Kuramitsu S; Miyauchi K; Yokoi H; Suwa S; Nishizaki Y; Yokoyama T; Nojiri S; Iwabuchi M; Shirai S; Ando K; Okazaki S; Tamura H; Watada H; Daida H
    J Cardiol; 2017 Jan; 69(1):369-376. PubMed ID: 27641967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of sitagliptin on carotid intima-media thickness in patients with coronary artery disease and impaired glucose tolerance or mild diabetes mellitus.
    Ishikawa S; Shimano M; Watarai M; Koyasu M; Uchikawa T; Ishii H; Inden Y; Takemoto K; Murohara T
    Am J Cardiol; 2014 Aug; 114(3):384-8. PubMed ID: 24929624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Bethel MA; Green JB; Milton J; Tajar A; Engel SS; Califf RM; Holman RR;
    Diabetes Obes Metab; 2015 Apr; 17(4):395-402. PubMed ID: 25600421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α
    Lovshin JA; Rajasekeran H; Lytvyn Y; Lovblom LE; Khan S; Alemu R; Locke A; Lai V; He H; Hittle L; Wang W; Drucker DJ; Cherney DZI
    Diabetes Care; 2017 Aug; 40(8):1073-1081. PubMed ID: 28550195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation of Copeptin with Diabetic and Renal Function Markers Among Patients with Diabetes Mellitus Progressing Towards Diabetic Nephropathy.
    Noor T; Hanif F; Kiran Z; Rehman R; Khan MT; Haque Z; Nankani K
    Arch Med Res; 2020 Aug; 51(6):548-555. PubMed ID: 32505416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.